Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome P450 3A25 is a member of the cytochrome P450 superfamily of enzymes, which catalyze the oxidation of xenobiotics, steroids, and lipids through monooxygenase reactions using a heme-thiolate structure[1][2][4]. While cytochrome P450 enzymes are critical for drug metabolism (notably human CYP3A4 and CYP3A5[2]), CYP3A25 itself is primarily characterized in rodents and serves as a counterpart to the human CYP3A subfamily. It is involved in the hepatic metabolism of various endogenous and exogenous compounds. The cytochrome P450 family as a whole is widely recognized for its key role in drug metabolism, pharmacokinetic variability, and potential drug–drug interactions[2][4]. CYP enzymes reside mainly in the liver and intestines, where they help clear potentially toxic substances and drugs from the body[1][2]. CYP3A25 is the rodent ortholog of the human CYP3A family; in humans, the most prominent enzymes are CYP3A4 and CYP3A5[2][4]. CYP3A25 is not a human protein, but the structured classification and biochemical roles largely parallel those of the characterized human CYP3A subtypes. This is relevant for translational and comparative studies, especially for preclinical drug metabolism. If you require information specifically about human drug targets, refer to CYP3A4 or CYP3A5 instead[2][4]. "Cytochrome P450 3A25" is a valid canonical name for this specific enzyme in rodents. Standard abbreviation is CYP3A25. It is a member of the enzyme superfamily and is considered a drug-metabolizing target, mainly in preclinical (non-human) studies[1][2][4]. It does not have broadly accepted or clinically significant roles in human disease or drug interactions, but its human equivalents (CYP3A4/5) are extremely important in clinical pharmacology[2]. No direct biomarkers or clinically relevant safety concerns are unique to CYP3A25; general drug–drug interaction principles apply to cytochrome P450 enzymes[2][4].
Monooxygenase activity (adds an oxygen atom in substrate metabolism); Oxidation of endogenous and exogenous compounds
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytochrome P450 3A25 (CYP3A25).